ABT-888 (veliparib)With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian TubeCancer, Triple-NegativeBreast Cancer, and Low-Grade Non-Hodgkin's Lymphoma
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Participants must be diagnosed with BRCA1/2 ovarian cancer, primary peritoneal or ovarian high-grade carcinoma, or fallopian tube cancer whose disease has progressed after at least one line of therapy.
Type of study:
Randomized, Phase II trial
Participants who have BRCA-positive ovarian cancer, primary peritoneal or ovarian high-grade serous carcinoma, or fallopian tube cancer will be randomized to receive either the combination of ABT-888 and cyclophosphamide, or cyclophosphamide alone
For all study sites, please contact:
Deborah E. Allen, R.N. (301) 402-5640 email@example.com
University of California, Davis
Davis, California, 95616
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612
University of Chicago
Chicago, Illinois, 60637
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Mayo Clinic, Rochester
Rochester, Minnesota, 55905
University of Nebraska Med. Ctr. Eppley Cancer Ctr.
Omaha, Nebraska, 68198-5950
Montefiore Medical Center
Bronx, New York, 10467
Memorial Sloan Kettering Cancer Center
New York, New York, 10021
Ohio State University
Columbus, Ohio, United States, 43210-1240
MD Anderson Cancer Center
Houston, Texas, 77030-4096
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.